Clear Search

Showing 2 results for “Chan JC”.

March 2022

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

Kidney Int Rep 2022;7:36–45 doi.org/10.1016/j.ekir.2021.10.008

Finerenone was associated with a 31% greater reduction in urine albumin:creatinine ratio (UACR) from baseline to Month 4 versus placebo. With similar reductions in UACR seen whether the patient was receiving SGLT2i at baseline or not.

more…

January 2022

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

N Engl J Med 2017;377:1228–39 DOI: 10.1056/NEJMoa1612917

The EXSCEL study showed that among patients with type 2 diabetes (T2D) with or without previous cardiovascular (CV) disease, the incidence of major adverse cardiovascular events (MACE) did not differ significantly between patients who received exenatide and those who received placebo.

more…